Renaissance Capital logo

Checkmate Pharmaceuticals Priced, Nasdaq: CMPI

Clinical stage immuno-oncology biotech developing therapies for solid tumors.

Industry: Health Care

First Day Return: -6.7%

We are a clinical-stage biotechnology company focused on developing and commercializing our proprietary technology to harness the power of the immune system to combat cancer. Our product candidate, CMP-001, is a differentiated Toll-like receptor 9, or TLR9, agonist delivered as a biologic virus-like particle, or VLP, utilizing a CpG-A oligonucleotide as a key component. When injected into a tumor, CMP-001 is designed to trigger the body’s innate immune system, thereby altering the tumor microenvironment and directing activated anti-tumor T cells to attack both the injected tumor and also tumors throughout the body. In a clinical trial of CMP-001 in combination with a systemic checkpoint inhibitor, or CPI, in patients whose tumors were unresponsive or no longer responsive to a CPI, we have observed a best overall response rate of 28%, including post-progression responders. We have assembled a strong management team and infrastructure to evaluate CMP-001 across multiple tumor types in combination with other immunotherapy agents. Our goal is to establish CMP-001 as a foundational immuno-oncology therapy that engages the innate immune system to fight cancer and improve outcomes for patients with a broad range of solid tumors.

Checkmate Pharmaceuticals (CMPI) Performance

Created with Highcharts 10.3.2Chart context menuCMPI vs. IPO Index (IPOUSA)Oct '20Jan '21Apr '21Jul '21Oct '21Jan '22Apr '22Jul '22Oct '22Jan '23Apr '23Jul '23Oct '23Jan '24Apr '24Jul '24Oct '24Jan '25-50%0%+ 50%-100%+ 100%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexOur ETF tracks the IPO Index